Abstract
Over a period of four years, 91 patients with inoperable or nonresectable lung cancer (55 bronchogenic and 36 metastatic) were treated by the continuous regional intra-aortic infusion of fluorouracil and cyclophosphamide, or both, for the purpose of increasing and prolonging the concentration of these agents in tumor-bearing areas supplied by the bronchial arteries. Twelve of the patients with bronchogenic cancer showed an objective response rate of 12.4 months' duration with an average survival time of 13.4 months. In the metastatic group, the cancers of 12 patients had an average objective regression of 12.5 months' duration with an average survival time of 14.5 months. A comparable retrospective study of the intravenous method of administration demonstrated no objective response (by our criteria) in 49 cases of bronchogenic and seven cases of metastatic lung cancer. Average survival time was 4.2 and 4.4 months, respectively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
